Subscribe to Newsletter
Business & Profession Professional Development

The Month in Business

0214-202-img.1

Already 2014 has seen a number of big business decisions being made in ophthalmology:

  • Carl Zeiss Meditec AG purchased the American IOL manufacturer, Aaren Scientific, for US$70 million.
  • Niche generic pharmaceutical company, Akorn, acquired all rights for Betimol (timolol ophthalmic solution) from Santen.
  • Alimera Sciences raised approximately US$37.5 million, “as working capital for the commercialization of Iluvien in Europe and the ongoing pursuit of FDA approval in the United States”, according to Dan Myers, Alimera’s President and CEO.
  • Ophthotech reached an enrolment milestone in the phase III safety and efficacy trial of Fovista (E10030), an anti-platelet-derived growth factor (PDGF). Making the milestone triggered a US$41.7 million payment from its partner, Novo A/S.
Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: